WebJan 8, 2005 · Commissioned by the CDF for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer who are in response to first-line platinum-based chemotherapy in line with NICE TA673, for BRCA mutation +ve patients [NIR3] ... [BlueTeq Form] NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian … WebThis is the most recent version of the national Cancer Drugs Fund list, and replaces any earlier versions. It contains updates to the previous list, as well as new drugs and …
Online Banking CDC Federal Credit Union in Atlanta
WebThis regimen is funded via CDF interim Funding. Requires Blueteq approval TREATMENT INTENT Disease modification GENERAL PRE-ASSESSMENT 1. Ensure all the following staging investigations are done: o FBC & film o Clotting screen o U&Es o LFTs o Calcium o Albumin o Uric acid o CRP o Baseline random blood glucose level WebRequires Blueteq approval The CDF criteria mandate that all 3 drugs in the combination (i.e. ixazomib, lenalidomide and dexamethasone) must be commenced at the same time and Ixazomib cannot be added in as an additional agent in the treatment of patients who have already previously commenced thermo scientific revertaid mm
The London Cancer Drug Fund Team Go Live with Blueteq!
WebLicensed / NICE TA451 (BLUETEQ required) Treatment of chronic, accelerated or blast phase Chronic Myeloid Leukaemia (CML) if o the disease is resistant to Dasatinib or Nilotinib, or o the patient cannot have Dasatinib or Nilotinib and Imatinib is not clinically appropriate, or o T315I gene mutation is present WebJan 8, 2005 · for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in patients >12 years old which are locally advanced/metastatic or not suitable for surgery, previously untreated with an NRTK inhibitor and have no other suitable treatment options (NICE TA644) [CDF] Use BlueTeq form [ENT1a] to initiate new patients http://www.chemodataset.nhs.uk/view?rid=274 thermo scientific rgl5004a